XTX Topco Ltd Raises Stock Position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

XTX Topco Ltd lifted its position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 52.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 52,004 shares of the company’s stock after buying an additional 17,950 shares during the period. XTX Topco Ltd owned approximately 0.10% of Milestone Pharmaceuticals worth $42,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Cubist Systematic Strategies LLC purchased a new position in shares of Milestone Pharmaceuticals in the 4th quarter worth approximately $73,000. Northern Trust Corp boosted its stake in Milestone Pharmaceuticals by 112.6% in the 4th quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock worth $137,000 after purchasing an additional 30,772 shares in the last quarter. Boxer Capital Management LLC acquired a new stake in Milestone Pharmaceuticals in the 4th quarter worth approximately $729,000. Finally, Toronto Dominion Bank acquired a new stake in Milestone Pharmaceuticals in the 4th quarter worth approximately $1,770,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Stock Performance

Shares of NASDAQ MIST opened at $1.70 on Friday. The company has a current ratio of 4.97, a quick ratio of 4.67 and a debt-to-equity ratio of 4.06. Milestone Pharmaceuticals Inc. has a 12 month low of $0.63 and a 12 month high of $2.75. The company has a 50 day simple moving average of $1.71 and a two-hundred day simple moving average of $1.60. The stock has a market cap of $90.89 million, a price-to-earnings ratio of -2.02 and a beta of 0.52.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). As a group, analysts predict that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright upgraded shares of Milestone Pharmaceuticals to a “buy” rating and set a $5.00 target price for the company in a research note on Thursday, June 5th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $7.00.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.